Route and product review

Oral BPC-157 and Capsules: What Is Actually Known

Capsules are the version most people encounter first, because they look like a supplement and arrive like one. Two things are worth knowing before that framing settles: BPC-157 is not a lawful dietary ingredient, and no human study has measured whether the oral form is absorbed.

  • Not a dietary ingredientHow the Department of Defense describes BPC-157
  • Under 30 minReported plasma half-life, from the 2025 systematic review
  • Certain routesThe FDA ties immunogenicity risk to how a peptide is given
  • InjectionThe route used by the only trial now testing BPC-157 in people

The short version

A capsule is not a gentler version of an injection. It is a different product with a different regulatory status, a different set of unanswered pharmacological questions, and no human data of its own.

The capsule format does real persuasive work. A bottle with a supplement facts panel reads as something the system has looked at. In this case the system has looked at it and reached the opposite conclusion, which is the thing the packaging obscures.

BPC-157 is not a lawful dietary ingredient

This is the clearest fact on the page, and it comes from the Department of Defense’s Operation Supplement Safety, which exists to tell service members what they can and cannot take.

What the DoD says

“BPC-157 is not a dietary ingredient. It is an unapproved drug and cannot be legally prescribed or sold over the counter.”

The mechanism behind that is worth understanding, because it turns on something we documented elsewhere on this site. United States supplement law contains an exclusion: an article that was authorised for investigation as a new drug, and became the subject of substantial public clinical investigation, cannot subsequently be marketed as a dietary ingredient. The rule exists to stop a compound being run through drug development and then sold as a supplement when that proves inconvenient.

Worth knowing

The same 2015 Phase 1 trial that never published its safety results is the drug investigation that sits behind this exclusion. The study that failed to tell anyone whether BPC-157 is safe is the reason it cannot be sold as a supplement.

We are describing the mechanism rather than issuing a legal opinion — whether any particular product meets the exclusion is a determination for the FDA, not for us. What is not in dispute is the outcome: the agencies that have addressed it say BPC-157 does not belong in a supplement. The full trial record is on our side effects page.

What the label on the bottle is doing

Because the supplement route is closed, oral BPC-157 products tend to arrive with one of two framings. Some are sold as supplements anyway. Others carry the research-chemical disclaimer, which the Department of Defense describes directly:

What the DoD says

“Products containing BPC-157 might be labeled as ‘research chemicals’ and carry statements such as ‘Not for human consumption,’ ‘Research use only,’ or ‘For research purposes only.'”

A capsule labelled not for human consumption is an unusual object. The format exists for one purpose, and the label denies that purpose. That disclaimer is not a safety warning to the buyer; it is a legal position for the seller, and it works by asserting that whatever happens next was not the intended use.

The practical consequence is the part that matters. A product sold on those terms has no manufacturer standing behind its use in a person, no obligation to collect reports if something goes wrong, and no recall pathway of the kind that applies to medicines and to supplements alike.

Does an oral peptide survive the gut?

This is the question the capsule format has to answer, and for BPC-157 it has not been answered in humans. What follows is the general problem and the specific evidence, kept apart so the difference is visible.

The general problem is that the digestive tract is built to take proteins apart. Peptides are chains of amino acids, and the enzymes in the stomach and small intestine break those chains for a living. This is why insulin is injected rather than swallowed, and why oral versions of peptide drugs have required substantial formulation work to exist at all. It is a real and well-recognised obstacle, not a talking point invented to disparage capsules.

The specific evidence is thinner than either side of the argument tends to admit. BPC-157 is described in the research literature as unusually stable in gastric juice, which is the basis of the claim that it can be taken by mouth. That claim has a plausible origin: the compound was derived from a protein found in gastric juice in the first place. What we could not find is a human study measuring how much of an oral dose reaches the bloodstream.

The honest position

Stable in gastric juice and absorbed into the bloodstream are two different claims. The first has support in the literature. The second is what a capsule depends on, and we found no human measurement of it.

There is also the half-life to account for. The 2025 systematic review reports a plasma half-life of under 30 minutes, with metabolism in the liver and clearance by the kidneys. Anything swallowed reaches the liver before it reaches the rest of the body, which is the point at which an oral product has the most to prove and the least data.

Route is not a detail the FDA treats lightly

The agency’s Category 2 entry for BPC-157 says compounded products “may pose risk for immunogenicity for certain routes of administration,” and that it “has identified no, or only limited, safety-related information for the proposed routes of administration.”

The phrase “certain routes” is doing deliberate work. The FDA is not treating BPC-157 as a single thing with a single risk profile; it is saying the risk depends on how the substance enters the body. That cuts both ways for capsules, and we are not going to pretend it points cleanly in one direction. It means an oral product is not automatically safer than an injected one, and it also means the injected safety questions do not transfer wholesale to the oral form.

What can be said plainly is which route is being taken seriously in research. The Phase 2 trial that began in February 2026 — the first properly designed human test of BPC-157 for anything — administers it by subcutaneous injection. Nobody is running a trial of the capsules.

What is actually in a capsule

Everything above assumes the capsule contains what the label says. That assumption carries the same problems as any other BPC-157 product, plus one the vials do not have.

  • Which BPC-157. The name is a common name rather than a United States Adopted Name, and more than one substance is sold under it — free base and acetate among them. A capsule label naming “BPC-157” does not identify the substance inside with any precision. This is covered in the overview.
  • Impurities and characterisation. The FDA lists peptide-related impurities and active ingredient characterisation among its unresolved concerns. Those apply regardless of the container the peptide arrives in.
  • The excipients. A capsule is not just its active ingredient — it is a shell, fillers, flow agents and whatever else the manufacturing required. In a product that sits outside supplement and drug regulation alike, none of that is disclosed to any standard.
  • No independent verification. The 2025 systematic review names unregulated manufacturing and contamination as sources of possible harm, separately from anything the peptide itself might do. A third-party certificate of analysis supplied by the seller is not independent verification.

What this page will not tell you

  • How many capsules to take, or how an oral amount compares to an injected one. No completed human trial has established either.
  • Which brand of capsule is better made, better tested, or more likely to contain what it claims. We do not review these suppliers.
  • Where to buy oral BPC-157, or how to import it.
  • Whether capsules are the safer choice for you. Route-specific risk is exactly what the FDA says it lacks the information to judge, and we are not better placed than the agency.

Sources and method

  • Supplement and labeling status. The Department of Defense’s Operation Supplement Safety, quoted directly for the dietary-ingredient statement and the research-chemical labeling.
  • Route and immunogenicity. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA. The “certain routes of administration” language is the agency’s own.
  • Half-life and manufacturing risk. Vasireddi and colleagues, Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review, HSS Journal, 2025.
  • The route used in trial. NCT07437547 on ClinicalTrials.gov, which specifies subcutaneous administration.
  • What we could not verify. We did not find a human study measuring oral bioavailability of BPC-157, but an absence we could not find is weaker evidence than a study we read. We have not established which routes the preclinical studies used, and we do not assert that the animal literature is exclusively injected or exclusively oral. We describe the drug-exclusion rule as the mechanism cited for the supplement position; we are not asserting a legal conclusion about any specific product. We have not tested any capsule.
  • Method. Regulatory statements are quoted from the agencies that issued them. Where the evidence supports a narrower claim than the one commonly made, this page states the narrower claim and says what the wider one would require.

BPC-157 overview →   BPC-157 side effects →   BPC-157 benefits →

Regulatory and literature sources checked 30 August 2026. We recheck this page if oral bioavailability data is published.